Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Luspatercept - Acceleron Pharma/Celgene Corporation

Next Previous
X
Search
Drug Profile

Luspatercept - Acceleron Pharma/Celgene Corporation

Alternative Names: ACE-536; BMS-986346; Luspatercept-aamt; REBLOZYL; Reblozyl

Latest Information Update: 15 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Bristol-Myers Squibb; Celgene Corporation
  • Class Antianaemics; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Beta-thalassaemia; Myelodysplastic syndromes
  • Phase III Myelofibrosis
  • Phase II Alpha-thalassaemia
  • No development reported Sickle cell anaemia

Most Recent Events

  • 31 May 2024 Efficacy data from the phase III COMMANDS trial in Myelodysplastic syndromes presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 02 Apr 2024 Registered for Myelodysplastic syndromes (Treatment-naive) in European Union, Liechtenstein, Norway, Iceland (SC)
  • 23 Feb 2024 Committee for Medicinal Products for Human Use recommends approval of Luspatercept for Myelodysplastic syndromes in European Union

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top